News & Updates
Filter by Specialty:
Sotagliflozin may offer cardiorenal protection for adults with T1D
Using the Steno T1 Risk Engines, the dual SGLT*1 and SGLT2 inhibitor sotagliflozin showed potential in reducing the risk of cardiovascular (CV) and renal disease in adults with type 1 diabetes (T1D).
Sotagliflozin may offer cardiorenal protection for adults with T1D
13 Oct 2022
Add-on digital therapeutics more cost-effective than standard treatment for essential hypertension
The combination of digital therapeutics (DTx) with the treatment-as-usual (TAU) strategy for essential hypertension is more cost-effective than TAU alone, a recent Japan study has found.
Add-on digital therapeutics more cost-effective than standard treatment for essential hypertension
13 Oct 2022
Early noninferior to delayed NOAC initiation after stroke in AF patients
Early initiation of nonvitamin K antagonist oral anticoagulants (NOACs) after acute ischaemic stroke in patients with atrial fibrillation (AF) appears to yield similar outcomes when compared with delayed initiation, as shown in the results of the TIMING* study.
Early noninferior to delayed NOAC initiation after stroke in AF patients
13 Oct 2022
Lebrikizumab efficacy in atopic dermatitis maintained at 1 year
Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.
Lebrikizumab efficacy in atopic dermatitis maintained at 1 year
12 Oct 2022
Carvedilol reduces decompensation, death in cirrhosis patients with hypertension
Long-term treatment with carvedilol lowers the risk of decompensation of cirrhosis and improves survival in compensated patients with clinically significant portal hypertension (CSPH), reports a study.